Skip to main content
Full access
Professional News
Published Online: 19 January 2001

While Ecstasy Gains Popularity, Troubling Side-Effect Data Emerge

While the use of most illicit drugs is declining or holding steady among the nation’s teenagers (see story above), the so called “club drug” referred to by the street name “Ecstasy” is soaring in popularity. It is most often used, according to the National Institute on Drug Abuse (NIDA), by young adults and adolescents at clubs, raves, and rock concerts.
Ecstasy, also known as “XTC,” “X,” “clarity,” “lover’s speed,” and “Adam” on the street, is a synthetic, psychoactive drug with both amphetamine and hallucinogenic properties. Its chemical name, methylenedioxymethamphetamine, is usually abbreviated as MDMA. The drug is similar to two other synthetic amphetamine-like drugs known to cause brain damage, methamphetamine and MDA, MDMA’s parent chemical.
First synthesized and patented in the early 1900s by the pharmaceutical industry, MDMA is usually taken orally as a tablet or capsule.
Its effects, which last acutely for approximately three to six hours, include euphoria, increased libido, increased energy, lack of inhibitions, and other side effects that are similar to those seen with other stimulants. These side effects include increased heart rate and blood pressure, muscle tension, involuntary teeth clenching, nausea, blurred vision, rapid eye movements, faintness, and chills or excessive sweating. In high doses it may lead to extremely elevated body temperature, dehydration, seizures, and ultimately cardiovascular and renal failure leading to coma and death.
In lower doses, perhaps its most dangerous long-term actions are its psychoactive effects. Research has shown that it may cause profound confusion and memory loss, depression, anxiety, paranoia, mania, sleep disturbances, and psychotic episodes, weeks and even months after it has been used.
The extreme variety of MDMA’s psychotropic effects are thought to be related to its neurotoxicity. Chronic use of MDMA has been found to produce long-term, most likely permanent, damage to serotonergic neurons in the brains of both animals and humans. It is probably this interaction with the serotonin system that yields the drug’s reported effects of heightened sexual experience, tranquility, and conviviality. Preliminary research, supported by NIDA, has shown that MDMA also causes degeneration of dopaminergic neurons in the brain.
“The recent increases in MDMA use are certainly of great concern,” said Alan I. Leshner, Ph.D., director of NIDA. “Our research shows that Ecstasy is a very dangerous drug; it is not a fun drug.” ▪

Information & Authors

Information

Published In

History

Published online: 19 January 2001
Published in print: January 19, 2001

Notes

The more we learn about the drug Ecstasy, the more powerful and dangerous it appears. This has yet to dampen its popularity with American teenagers among whom its use continues to skyrocket.

Authors

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

There are no citations for this item

View Options

View options

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share